Outcomes and predictors of mortality after transcatheter aortic valve implantation: Results of the Brazilian registry

• Published in: Catheterization and cardiovascular interventions 2015-04, Vol.85 (5), p.E153-E162
• Main Authors: de Brito Jr, Fábio S., Carvalho, Luiz A., Sarmento-Leite, Rogério, Mangione, José A., Lemos, Pedro, Siciliano, Alexandre, Caramori, Paulo, São Thiago, Luiz, Grube, Eberhard, Abizaid, Alexandre
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; aortic valve disease; Aortic Valve Stenosis - mortality; Aortic Valve Stenosis - surgery; Brazil - epidemiology; Chronic obstructive pulmonary disease; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Medical research; Mortality; percutaneous intervention; percutaneous valve therapy; Postoperative Complications - mortality; Registries; Retrospective Studies; Risk Factors; Survival Rate - trends; Time Factors; Transcatheter Aortic Valve Replacement; transcatheter valve implantation
• ISSN: 1522-1946; 1522-726X
• DOI: 10.1002/ccd.25778

Objective The study sought to evaluate outcomes and predictors of mortality after transcatheter aortic valve implantation (TAVI). Background TAVI registries can reliably address outcomes and issues that adversely affect results in real‐life. Methods All endpoints and complications were analyzed according to Valve Academic Research Consortium‐2 criteria. Results Between January 2008 and January 2013, 418 patients underwent TAVI in 18 centers and were included in the Brazilian registry. The transfemoral approach was used in 96.2% of the procedures. The CoreValve and Sapien XT prosthesis were used in 360 (86.1%) and 58 (13.9%) cases, respectively. All‐cause mortality at 30 days and 1 year were 9.1 and 21.5%. Chronic obstructive pulmonary disease (COPD) (HR: 3.50), acute kidney injury (AKI) (HR: 3.07), stroke (HR: 2.71) and moderate/severe paravalvular regurgitation (PVR) (HR: 2.76) emerged as independent predictors of overall mortality. COPD (OR: 3.00), major vascular complications (OR: 7.99) and device malpositioning (OR: 6.97) were predictors of early (≤30 days) mortality, while COPD (HR: 2.68), NYHA class III/IV (HR: 3.04), stroke (HR: 4.15), AKI (HR: 2.44) and moderate/severe PVR (HR: 3.20) impacted late (>30 days) mortality. The use of transesophageal echocardiogram (TEE) to monitor the procedure was found to be a protective factor against overall (HR: 0.57) and late (HR: 0.47) mortality. Conclusion This multicenter registry reflected a real‐life national TAVI experience. Comorbidities, periprocedural complications and moderate/severe PVR were associated with increased mortality and the use of TEE to monitor the procedure acted as a protective factor. © 2014 Wiley Periodicals, Inc.